Fish Oil and Cardiovascular Suboptimal Health

Overview

The purpose of this study is to determine whether omega-3 fatty acids supplementation are effective in the improvement of suboptimal health status and cardiovascular risk.

Full Title of Study: “Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 Fatty Acids in Subjects at High Cardiovascular Risk and Suboptimal Health Status”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: July 2015

Detailed Description

The Suboptimal health status questionnaire (SHSQ-25) is used to evaluate the suboptimal health status. The SHSQ-25 includes 25 questions. The score of the SHSQ-25 is from 0 to 100. Suboptimal health status is defined as the SHSQ-25 score above than 35. The higher scores of the SHSQ-25 one gets, the more severity of suboptimal health status he/she has. All participants are asked to fill in the SHSQ-25 before and after the intervention. If the score decreases after the intervention, it means that the suboptimal health status has been improved.

Interventions

  • Dietary Supplement: Omega -3 fatty acids
    • Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.
  • Dietary Supplement: Placebo: Corn oil
    • Each subject assigned to the control group will receive 4 g/day capsule of corn oil.

Arms, Groups and Cohorts

  • Experimental: Omega-3 fatty acid capsules
    • Omega-3 fatty acid capsules, 4 g/day, requiring intake 2 capsules (1g each one) in the morning and two at night for 3 months.
  • Placebo Comparator: corn oil
    • Corn oil in similar presentation as omega-3 fatty acid capsules, requiring intake 2 capsules in the morning and two at night for 3 months.

Clinical Trial Outcome Measures

Primary Measures

  • the improvement of suboptimal health status
    • Time Frame: three months
    • The improvement of suboptimal health status is evaluated by the change of the SHSQ-25 scores after intervention.
  • the improvement of traditional cardiovascular risk factors
    • Time Frame: three months
    • To investigate the changes of traditional cardiovascular risk factors such as blood pressure, lipids, fasting plasma glucose, and body mass index with three months supplementation of omega-3 fatty acids. Abnormal cardiovascular risk factors are defined according to the Adult Treatment Panel III criteria for metabolic syndromes and the recommendation by the Working Group on Obesity in China. The number of abnormal cardiovascular risk factors for each participant is recorded before and after intervention. If the number decreases after intervention, it means that the traditional cardiovascular risk factors have been improved.

Participating in This Clinical Trial

Inclusion Criteria

1. suboptimal health status, defined as the score of suboptimal health questionnaire ≥35. 2. at least one of cardiovascular risk factors:

  • overweight or obesity, defined as body mass index (BMI) ≥25 kg/m2. – systolic blood pressure ≥130 and <140 mmHg and diastolic blood pressure <90 mmHg, or diastolic blood pressure ≥85 and <90 mmHg and systolic blood pressure <140 mmHg – fasting plasma glucose ≥100 and <126 mg/dL – total cholesterol ≥200 and <240 mg/dL, triglyceride ≥150 and <200 mg/dL, low density lipoprotein-cholesterol ≥130 and <160 mg/dL,and/or high density lipoprotein-cholesterol <40 mg/dL 3. written informed consent Exclusion Criteria:

1. history of system diseases, such as cardiovascular diseases, digestive system diseases, diseases of respiratory system, blood and immune system diseases, nervous system diseases, endocrine system diseases, and diseases of the genitourinary system. 2. history of mental illness. 3. pregnant or breastfeeding. 4. use of antihypertensive, antidiabetic, or lipid-lowering drugs within the past two weeks. 5. use of fish oil capsules or other supplements containing omega-3 fatty acids within the past two weeks. 6. allergy or intolerance to fish oil, corn oil, omega-3 fatty acids, or vitamin E. 7. participation in another trial. 8. unable to promise to not use drugs and other fish oils during the study. 9. unable to provide informed written consent.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Chinese PLA General Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Qiang Zeng, MD, Professor – Chinese PLA General Hospital
  • Overall Official(s)
    • Qiang Zeng, M.D, Principal Investigator, Chinese PLA General Hospital
    • Sheng-Yong Dong, M.D, Principal Investigator, Chinese PLA General Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.